Mylan Inc. Sept. 7 announced that it has completed the acquisition of Bioniche Pharma Holdings Ltd. sooner than anticipated.
Bioniche Pharma, an injectable pharmaceutical company, is providing Mylan with immediate entry into the North American injectables market and a platform for the commercialization of future biosimilar product offerings, Pittsburgh-based Mylan said. On July 14, Mylan announced its plan to acquire Bioniche Pharma for $550 million in cash (8 PLIR 966, 7/23/10).
Mylan also announced that it is officially launching its Mylan Institutional business, a newly created platform focused on providing a differentiated product offering tailored to institutional customers ...
Learn more about Bloomberg Law or Log In to keep reading:
See Breaking News in Context
Bloomberg Law provides trusted coverage of current events enhanced with legal analysis.
Already a subscriber?
Log in to keep reading or access research tools and resources.